Official Title
Restoration of Endothelial Integrity in Patients With COVID-19 (RELIC)
Brief Summary

This is a pilot study designed to demonstrate the feasibility of conducting a larger study of standard plasma therapy in COVID-19 patients.

Detailed Description

This is a randomized trial in hospitalized COVID-19-positive patients. This trial compares
standard care to standard care plus an infusion of non-convalescent thawed plasma. Blood will
be collected from all participants at eight timepoints, and clinical data will be collected
for 30 days or until discharge/death.

Withdrawn
COVID-19

Biological: Thawed plasma

Plasma not labeled "convalescent plasma" is presumed to be free of COVID antibodies, but is not tested for antibodies. To ensure that we are using antibody-free plasma, we will test each unit of plasma with a quick COVID test before it is utilized in this study.

Eligibility Criteria

Inclusion Criteria:

- 18 years of age or older

- COVID-19 positive by PCR or assay within 72 hours or less

- Oxygen saturation of ≤94% on room air or requiring supplemental oxygen at screening

Exclusion Criteria:

- mechanically ventilated

- pregnant

- prisoners

- receiving resuscitation with blood products for hemorrhagic shock

- receiving an investigational therapy for COVID-19

- diagnosed with severe comorbidities

- not expected to survive more than 24 hours

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A

Rondi Gelbard, MD, Principal Investigator
University of Alabama at Birmingham

University of Alabama at Birmingham
NCT Number
Keywords
plasma
MeSH Terms
COVID-19